The latest price target for TC BioPharm (Holdings) (NASDAQ:TCBP) was reported by HC Wainwright & Co. on December 6, 2024. The analyst firm set a price target for $3.00 expecting TCBP to rise to within 12 months (a possible 552.32% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for TC BioPharm (Holdings) (NASDAQ:TCBP) was provided by HC Wainwright & Co., and TC BioPharm (Holdings) maintained their buy rating.

There is no last upgrade for TC BioPharm (Holdings)

There is no last downgrade for TC BioPharm (Holdings).

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TC BioPharm (Holdings), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TC BioPharm (Holdings) was filed on December 6, 2024 so you should expect the next rating to be made available sometime around December 6, 2025.

While ratings are subjective and will change, the latest TC BioPharm (Holdings) (TCBP) rating was a maintained with a price target of $7.00 to $3.00. The current price TC BioPharm (Holdings) (TCBP) is trading at is $0.46, which is out of the analyst’s predicted range.